Nektar Therapeutics (LTS:0UNL)
$ 1.0304 -0.0065 (-0.63%) Market Cap: 188.15 Mil Enterprise Value: 51.91 Mil PE Ratio: 0 PB Ratio: 3.86 GF Score: 53/100

Nektar Therapeutics Analysts Call with Expert Oncologist Panel During 2020 Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting Transcript

Nov 11, 2020 / 09:15PM GMT
Release Date Price: $17 (+1.01%)
Operator

Ladies and gentlemen, thank you for standing by and welcome to the Nektar Therapeutics SITC Analyst Call. (Operator Instructions) Please be advised that today's conference may be recorded. (Operator Instructions)

I would now like to hand the conference over to your speaker today, Ms. Jennifer Ruddock, Head of Corporate Affairs. Ma'am, you may begin.

Jennifer Ruddock
Nektar Therapeutics - SVP of Strategy & Corporate Affairs

Thank you, Krystal. Good afternoon, everyone, and thank you for joining us on today's analyst call to review data presented for Nektar's I-O pipeline at the 2020 SITC meeting.

Before we start, I'll remind you that this presentation includes forward-looking statements regarding Nektar's drug candidates bempegaldesleukin, NKTR-262 and NKTR-255 and other potential drug candidates; clinical trial results; the timing of the start of and plan for ongoing or planned clinical trials with partners; the therapeutic potential of our drug candidates; the timing and outcome of regulatory decisions; and future availability of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot